Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2020.100133Source: DataRank Database

Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations is a research paper published in JTO Clinical and Research Reports (2021). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.00)OA: goldTopics (22)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Susumu Kobayashi ORCID,Daniel B. Costa ORCID,Andrew J. Piper‐Vallillo

Live enrichment

PubMed:34589996 PMC:PMC8474188 OpenAlex:https://openalex.org/W3136610296

National Cancer Institute

Grant: R37 CA218707

FWCI

0.00

Citation Percentile

0.0%

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.jtocrr.2020.100133

publisherhttps://doi.org/10.1016/j.jtocrr.2020.100133

publisherhttps://api.elsevier.com/content/article/PII:S2666364320301843?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666364320301843?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34589996

Fields of Study

Lung Cancer Treatments and MutationsCancer Mechanisms and TherapyPI3K/AKT/mTOR signaling in cancer

Keywords

CrizotinibLung cancerOsimertinibMedicineExonAcquired resistanceScopusMutationCancerInternal medicineOncologyCancer researchMolecular biologyGeneticsBiologyMEDLINEGeneROS1Adenocarcinoma

Sustainable Development Goals

SDG 0: Good health and well-being

Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations

FAIR Checklist

Authors (3)

Funding (1 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)